MOLOGEN AG reports results of first six months 2007

Berlin, August 14, 2007 - The Berlin-based biotech company MOLOGEN AG has published today the results of the first six months 2007 prepared in accordance with the German Commercial Code (HGB).

The performance in the first half year 2007 was mainly influenced by higher costs of materials and personnel expenses in the area of Research and Development for pre-clinical tests and clinical studies. Additional costs were incurred due to one-time effects related to the capital increase and higher marketing expenses.

Liquid funds were kept above EUR 10 million at the end of the second quarter 2007. Proceeds from the sale of the subsidiary Vivotecnia Research S.L. (Spain) contributed to the development of liquid funds.

Results (comparison period: Jan 1 – June 30, 2006):

Operating result (EBIT) EUR -2.8 million (vs. EUR -1.7 million). Net loss EUR -2.6 million (vs. EUR -1.6 million). Sales EUR 0.1 million (vs. EUR 0.1 million). Other operating expenses EUR -1.4 million (vs. EUR -0.8 million). Other operative income EUR 0.6 million (vs. EUR 0.1 million). Liquid funds EUR 10.1 million (vs. 5.7 million). Equity ratio 95% (vs. 94%).

Download Half-year Report 2007

About MOLOGEN

MOLOGEN AG is a listed biopharmaceutical company with headquarters in Berlin (Frankfurt Stock Exchange, Regulated Market, ISIN DE0006637200). On the basis of patented technologies (MIDGE and dSLIM), MOLOGEN develops DNA-based vaccines and therapeutic agents for the prevention and treatment of a wide range of serious illnesses.

Disclaimer concerning prognoses

Certain statements in this communication contain formulations or terms referring to the future or future developments, as well as negations of such formulations or terms, or similar terminology. These are described as forward-looking statements. In addition, all information in this communication regarding planned or future results of business segments, financial classification numbers, developments of the financial situation, or other financial or statistical data contains such forward-looking statements. The company cautions prospective investors not to rely on such forward-looking statements as certain prognoses of actual future events and developments. The company is neither responsible nor liable for these forward-looking statements. It is not responsible for updating such information, which only represents the state of affairs on the day of publication.

back to the overview